Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

June 01, 1996; Volume 49,Issue 6
  • You have access
    High affinity open channel block by dofetilide of HERG expressed in a human cell line.
    D J Snyders and A Chaudhary
    Molecular Pharmacology June 1996, 49 (6) 949-955;
  • You have access
    A distinct G(i) protein-coupled receptor for sphingosylphosphorylcholine in human leukemia HL-60 cells and human neutrophils.
    C J Van Koppen, D Meyer Zu Heringdorf, C Zhang, K T Laser and K H Jakobs
    Molecular Pharmacology June 1996, 49 (6) 956-961;
  • You have access
    Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter.
    B D Stride, G Valdimarsson, J H Gerlach, G M Wilson, S P Cole and R G Deeley
    Molecular Pharmacology June 1996, 49 (6) 962-971;
  • You have access
    Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.
    R Danesi, D Nardini, F Basolo, M Del Tacca, D Samid and C E Myers
    Molecular Pharmacology June 1996, 49 (6) 972-979;
  • You have access
    Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439.
    I J Lee, K S Jeong, B J Roberts, A T Kallarakal, P Fernandez-Salguero, F J Gonzalez and B J Song
    Molecular Pharmacology June 1996, 49 (6) 980-988;
  • You have access
    Alteration by 2,3,7,8-Tetrachlorodibenzo-p-dioxin of CCAAT/enhancer binding protein correlates with suppression of adipocyte differentiation in 3T3-L1 cells.
    P C Liu, M A Phillips and F Matsumura
    Molecular Pharmacology June 1996, 49 (6) 989-997;
  • You have access
    D609, a phosphatidylcholine-specific phospholipase C inhibitor, blocks interleukin-1 beta-induced vascular cell adhesion molecule 1 gene expression in human endothelial cells.
    R R Cobb, K A Felts, G C Parry and N Mackman
    Molecular Pharmacology June 1996, 49 (6) 998-1004;
  • You have access
    Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon.
    P Kramata, I Votruba, B Otová and A Holý
    Molecular Pharmacology June 1996, 49 (6) 1005-1011;
  • You have access
    Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    F Ali-Osman, G Antoun, H Wang, S Rajagopal and E Gagucas
    Molecular Pharmacology June 1996, 49 (6) 1012-1020;
  • You have access
    Antagonist conformations with the beta(2)-adrenergic receptor ligand binding pocket.
    G H Hockerman, M E Girvin, C C Malbon and A E Ruoho
    Molecular Pharmacology June 1996, 49 (6) 1021-1032;
  • You have access
    A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter.
    R T Fremeau, M Velaz-Faircloth, J W Miller, V A Henzi, S M Cohen, J V Nadler, S Shafqat, R D Blakely and B Domin
    Molecular Pharmacology June 1996, 49 (6) 1033-1041;
  • You have access
    Regulation of 13(S)-hydroxyoctadecadienoic acid biosynthesis in Syrian hamster embryo fibroblasts by the epidermal growth factor receptor tyrosine kinase.
    W C Glasgow, E M Hill, S R McGown, K B Tomer and T E Eling
    Molecular Pharmacology June 1996, 49 (6) 1042-1048;
  • You have access
    Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate.
    S W Bahouth, Y Gokmen-Polar, E C Coronel and J N Fain
    Molecular Pharmacology June 1996, 49 (6) 1049-1057;
  • You have access
    Effect of cyclic GMP-increasing agents nitric oxide and C-type natriuretic peptide on bovine chromaffin cell function: inhibitory role mediated by cyclic GMP-dependent protein kinase.
    F Rodriguez-Pascual, M T Miras-Portugal and M Torres
    Molecular Pharmacology June 1996, 49 (6) 1058-1070;
  • You have access
    Biological and molecular analyses of structurally reduced analogues of endothelin-1.
    M A Forget, N Lebel, P Sirois, Y Boulanger and A Fournier
    Molecular Pharmacology June 1996, 49 (6) 1071-1079;
  • You have access
    Point mutations of the alpha 1 beta 2 gamma 2 gamma-aminobutyric acid(A) receptor affecting modulation of the channel by ligands of the benzodiazepine binding site.
    A Buhr, R Baur, P Malherbe and E Sigel
    Molecular Pharmacology June 1996, 49 (6) 1080-1084;
  • You have access
    Sparsomycin and its analogues: a new approach for evaluating their potency as inhibitors of peptide bond formation.
    S Kallia-Raftopoulos, D Synetos, H C Ottenheijm, L A van den Broek and C Coutsogeorgopoulos
    Molecular Pharmacology June 1996, 49 (6) 1085-1091;
  • You have access
    Restricted analogues provide evidence of a biologically active conformation of thyrotropin-releasing hormone.
    L Laakkonen, W Li, J H Perlman, F Guarnieri, R Osman, K D Moeller and M C Gershengorn
    Molecular Pharmacology June 1996, 49 (6) 1092-1096;
  • You have access
    Reactive oxygen species mediate stem cell factor synergy with granulocyte/macrophage colony-stimulating factor in a subpopulation of primitive murine hematopoietic progenitor cells.
    D W Pyatt, W S Stillman and R D Irons
    Molecular Pharmacology June 1996, 49 (6) 1097-1103;
  • You have access
    Thapsigargin modulates agonist-stimulated cyclic AMP responses through cytosolic calcium-dependent and -independent mechanisms in rat pinealocytes.
    A K Ho, T Ogiwara and C L Chik
    Molecular Pharmacology June 1996, 49 (6) 1104-1112;
  • You have access
    Metabolic activation of 2,6-dichlorobenzonitrile, an olfactory-specific toxicant, by rat, rabbit, and human cytochromes P450.
    X Ding, D C Spink, J K Bhama, J J Sheng, A D Vaz and M J Coon
    Molecular Pharmacology June 1996, 49 (6) 1113-1121;
  • You have access
    Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.
    P Chiba, G Ecker, D Schmid, J Drach, B Tell, S Goldenberg and V Gekeler
    Molecular Pharmacology June 1996, 49 (6) 1122-1130;
  • You have access
    An aspartate residue in the extracellular loop of the N-methyl-D-aspartate receptor controls sensitivity to spermine and protons.
    K Kashiwagi, J Fukuchi, J Chao, K Igarashi and K Williams
    Molecular Pharmacology June 1996, 49 (6) 1131-1141;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 49, Issue 6
1 Jun 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics